Revance Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Revance Therapeutics

08/11/2024 05:12

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.63.  The mean expectation of ten analysts
for the quarter was for a loss of 38 cents per share. Wall
Street expected results to range from -45 cents to -34 cents per
share.
    * Revenue rose 110.9% to $119.76 million from a year ago;
analysts
expected $68.84 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of 37 cents​.
    * The company reported a quarterly loss of $38.12 million.
    * Revance Therapeutics Inc shares had risen by 11.9% this
quarter and lost 33.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 25.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Revance
Therapeutics Inc is 6.66 
This summary was machine generated from LSEG data November 8 at
05:11 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.38          -0.37          Beat
 Jun. 30 2024      -0.53          -0.36          Beat
 Mar. 31 2024      -0.75          -0.58          Beat
 Dec. 31 2023      -0.72          -0.62          Beat